These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36427162)

  • 21. True vs. false immune-mediated thrombotic thrombocytopenic purpura exacerbations: a clinical case in the caplacizumab era.
    Laganà A; Trisolini SM; Maglione R; Mahnaz SB; Imperatore S; Vitullo D; Capria S
    Blood Coagul Fibrinolysis; 2024 Jan; 35(1):37-42. PubMed ID: 37994623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
    J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?
    Coppo P; Joly BS;
    Br J Haematol; 2023 Aug; 202(4):725-727. PubMed ID: 37291806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
    Coppo P; Bubenheim M; Azoulay E; Galicier L; Malot S; Bigé N; Poullin P; Provôt F; Martis N; Presne C; Moranne O; Benainous R; Dossier A; Seguin A; Hié M; Wynckel A; Delmas Y; Augusto JF; Perez P; Rieu V; Barbet C; Lhote F; Ulrich M; Rumpler AC; de Witte S; Krummel T; Veyradier A; Benhamou Y
    Blood; 2021 Feb; 137(6):733-742. PubMed ID: 33150928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.
    Bowyer A; Brown P; Hopkins B; Scully M; Shepherd F; Lowe A; Mensah P; Maclean R; Kitchen S; van Veen JJ
    Br J Haematol; 2022 May; 197(3):349-358. PubMed ID: 35262910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
    Mazepa MA; Park YA; Raval JS
    Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
    He J; Qi J; Han H; Xu X; Li X; Song X; Han Y
    Expert Rev Hematol; 2023 May; 16(5):377-385. PubMed ID: 37045600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
    Kühne L; Kaufeld J; Völker LA; Wendt R; Schönermarck U; Hägele H; Osterholt T; Eichenauer DA; Bieringer M; von Bergwelt-Baildon A; Fischereder M; Buxhofer-Ausch V; Menne J; Brinkkoetter PT; Knöbl P
    J Thromb Haemost; 2022 Apr; 20(4):951-960. PubMed ID: 35000278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caplacizumab as an add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review.
    Chavaz L; Cimasoni L; Kremer Hovinga JA; Coppo P; Ansari M
    Front Pediatr; 2024; 12():1448801. PubMed ID: 39233868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five years of caplacizumab - lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura.
    Völker LA; Brinkkoetter PT; Cataland SR; Masias C
    J Thromb Haemost; 2023 Oct; 21(10):2718-2725. PubMed ID: 37562668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caplacizumab as rescue therapy in refractory TTP involving neurologic features.
    Tran MH; Lee LX; Cao Y; Vu L; Pakbaz Z
    Transfus Apher Sci; 2023 Jun; 62(3):103656. PubMed ID: 36863912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful Treatment of Acquired Thrombotic Thrombocytopenic Purpura With Caplacizumab Combined With Plasma Exchanges and Immune Suppression in 3 Children.
    Kalinina II; Antonova KS; Avdonin PV; Klebanova EE; Kotskaya NN; Kurnikova EE; Shutova AD; Matveev VE; Maschan AA
    J Pediatr Hematol Oncol; 2024 Apr; 46(3):e220-e222. PubMed ID: 38447071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
    Poullin P
    Transfus Clin Biol; 2021 Nov; 28(4):380-385. PubMed ID: 34464709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effective and safe off-label use of caplacizumab treatment in a middle-aged obese male.
    Ostuni A; Tiscia G; Battista C; Favuzzi G; Montinaro V; Pronzo V; Cappucci F; Fischetti L; Gesualdo L; Grandone E
    Transfus Clin Biol; 2021 Feb; 28(1):89-91. PubMed ID: 33285299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world experience with caplacizumab in the management of acute TTP.
    Dutt T; Shaw RJ; Stubbs M; Yong J; Bailiff B; Cranfield T; Crowley MP; Desborough M; Eyre TA; Gooding R; Grainger J; Hanley J; Haughton J; Hermans J; Hill Q; Humphrey L; Lowe G; Lyall H; Mohsin M; Nicolson PLR; Priddee N; Rampotas A; Rayment R; Rhodes S; Taylor A; Thomas W; Tomkins O; Van Veen JJ; Lane S; Toh CH; Scully M
    Blood; 2021 Apr; 137(13):1731-1740. PubMed ID: 33150355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumab.
    Schimmer RR; Sutter T; Bachofner A; Ranieri E; Rodewald AK; Kremer Hovinga JA; Kimmich N; Trinchero A; Studt JD
    Br J Haematol; 2024 May; 204(5):1994-1998. PubMed ID: 38168722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
    Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
    Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues.
    Trisolini SM; Laganà A; Capria S
    Mediterr J Hematol Infect Dis; 2024; 16(1):e2024060. PubMed ID: 38984099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The standard of care for immune thrombotic thrombocytopenic purpura today.
    Zheng XL
    J Thromb Haemost; 2021 Aug; 19(8):1864-1871. PubMed ID: 34060225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.
    Pavenski K; Scully M; Coppo P; Cataland S; Knöbl P; Peyvandi F; Kremer Hovinga JA; de la Rubia J; Khan U; Marques AP; Gunawardena S
    Res Pract Thromb Haemost; 2024 Jul; 8(5):102512. PubMed ID: 39221451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.